July 15, 2022, Shanghai – Shanghai Taichu Bio-technology Co., Ltd. (referred to as "Taichu Group") and Ubrigene (Beijing) Cell Technology Co., Ltd. (referred to as "Ubrigene") formally announced a strategic collaboration. By leveraging their complementary strengths, the two companies aim to jointly promote the more standardized, orderly, robust, and efficient development of China's gene and cell therapy (CGT) industry.

Taichu Group is a large group enterprise focused on providing integrated CRDMO (Contract Research, Development & Manufacturing Organization) services for various new drug R&D and production. Ubrigene is a multinational R&D and manufacturing biotechnology company dedicated to the development and application of CGT technologies, offering comprehensive solutions.

Located in the Lingang Special Area of Shanghai, Taichu Bio boasts service facilities covering 54,500 square meters. The subsidiaries comprises of Taichu Group: AceMab, Tarlead, and TJR BIO, each specializing in distinct areas to provide services including non-clinical druggability evaluation (CRO), antibody drug discovery (CRO), antibody drug development and manufacturing (CDMO), and nucleic acid drug R&D and manufacturing (CDMO). Each company features a strong team led by internationally renowned experts and composed of dozens of senior specialists, capable of providing comprehensive technical support for non-clinical studies across various new drug R&D and production stages.

Ubrigene currently operates with its Beijing headquarters, manufacturing bases in Jinan and Suzhou, and global R&D centers in Maryland, USA, and Vancouver, Canada. Its expert team possesses over a decade of industrial experience in the CGT field, offering end-to-end services to gene therapy drug developers, including cell bank construction, process development, analytical method development, CDMO and IND application support, and commercial manufacturing of gene therapies. Ubrigene is a leading viral vector CDMO service provider in China's cell and gene therapy sector.

The leadership positions of both companies and their teams within the CGT CDMO industry provide a solid foundation for this collaboration. The partners will leverage their respective technological platform advantages, share market resources, and jointly support clients with upstream and downstream services such as "China-US dual IND submissions," "China-EU dual IND submissions," and clinical trials. Together, they will provide integrated, end-to-end solutions, offering powerful combined momentum to optimize and advance China's CGT industry and support its overseas expansion.

Dr. Jing Ma   CEO of Taichu Bio

"I am very pleased to establish this strategic partnership with Ubrigene. Our shared commitment to enabling customer success closely unites us scientists and entrepreneurs. I look forward to broader and deeper cooperation between our teams. I am confident that with our combined platforms and experience in the CGT industry, we will accelerate the global development of China's CGT sector, ultimately benefiting more patients."

Dr. Xiulian Sun   CEO of Ubrigene

"The Taichu Group possesses first-class technical and operational teams, along with an innovative service model covering the entire lifecycle and full industrial chain of biologics, demonstrating formidable strength. Ubrigene holds a leading domestic technological platform and extensive project experience in the CGT CDMO field, having provided full-process services for multiple clients' IND applications and clinical trials. Through this strategic collaboration, we aim to combine our respective strengths to empower the CGT industry. Leveraging our collective experience in overseas regulatory filings, we will support the global R&D and manufacturing of CGT therapies."